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Serum carboxypeptidase N (SCPN) is the primary 
inactivator of the C3a, C4a, and C5a anaphylatoxins as 
well as an inactivator of bradykinin. Thus SCPN defi- 
ciency potentia~dy could result in significant pathophysi- 
ologic consequences. Previous studies identified a defi- 
cient subject afflicted with frequent episodes of angio- 
edema, and other family members also had SCPN defi- 
ciency. To delineate this abnormality further, the frac- 
tional catabolic rate (FRC) and enzyme synthesis were 
determined in three members of the afflicted kindred as 
well as in five normal persons following the infusion of 
homogeneous 125I-SCPN. The mean FCR and synthesis 
rates for SCPN in the normal subjects were 1.3%/hr and 
20,793 U/kg/hr, respectively. Reduced synthesis was con- 
cluded to be primarily responsible for the low SCPN 
levels in the afflicted kindred. The high FRC of SCPN 
discourages attempted maintenance therapy with infu- 
sions of enriched SCPN preparations. 
KEY WORDS: Serum carboxypeptidase N; anaphylatoxin; an- 
gioedema. 
INTRODUCTION 
Serum carboxypeptidase N (SCPN), which also is 
referred to as anaphylatoxin inactivator, kininase I, 
and serum carboxypeptidase B, is the primary in 
vivo inactivator of C3a, C4a, and C5a. The enzyme 
also inactivates bradykinin, kallidin, fibrinopeptides 
A and B, and plasmin degradation products of fibrin 
by cleaving the C-terminal cationic amino acid. 
Postulating that a deficiency in this enzyme might 
predispose to anaphylactic or anaphylactoid reac- 
tions in humans, we have screened more than 500 
sera for SCPN activity, with special emphasis on 
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specimens from patients with chronic, idiopathic 
urticaria/angioedema or persons who have experi- 
enced anaphylactoid reactions from radiographic con- 
trast media. As reported previously (1), one individual 
with chronic, recurrent angioedema and urticaria was 
identified who had SCPN levels only about 21% of 
normal. A sister of the propositus also had low SCPN 
levels, and other family members had values interme- 
diate between that of the propositus and the normal 
range. The studies reported here were carried out to 
determine whether a defect in synthesis or excessive 
catabolism caused the low SCPN values in the family 
identified as deficient in SCPN activity. In addition to 
helping to elucidate the pathophysiologic defect in 
this kindred, knowledge of the fractional catabolic 
rate (FCR) would be helpful in assessing the feasi- 
bility of maintenance therapy with infusions of 
enriched SCPN preparations. Thus the FCR and 
rate of synthesis of SCPN were measured in several 
normal individuals as well as in the propositus 
(G.S.), his sister (A.P.), and his son (L.S.). 
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MATERIALS AND METHODS 
SCPN Purification. SCPN was purified from hu- 
man plasma by the method of Plummer and Hurwitz 
(2) and kindly provided to us by Dr. Plummer. It 
gave a single band on alkaline disc gel electropho- 
resis and a pattern identical to that previously 
reported (2) on 7.5% sodium dodecyl sulfate (SDS) 
gels following reduction. 
SCPN Iodination. A typical procedure consisted 
of incubating a mixture containing 50 txg SCPN in 
50 jxl 0.2 M phosphate buffer, pH 7.2, 10 ixl lzsI (100 
mCi/M; Amersham), 25 p.1 enzymobeads (Bio-Rad), 
and 25 p~l 1% a-D-glucose in pH 7.2 phosphate- 
buffered saline (PBS) for 40 min at room tempera- 
ture (RT). After adding 50 ~g SCPN carrier, the 
mixture was passed through a P10 column to re- 
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move free iodide, then eluted with PBS, and frac- 
tions containing t25I-SCPN were pooled; 25% salt- 
free human serum albumin (HSA) was added to a 
final concentration of 1.5% HSA. After centrifuga- 
tion in a sterile tube at 150,000g for 40 min at 4°C, 
the upper three-fourths of the material was har- 
vested and passed through a sterile 0.45-~m Milli- 
pore filter into sterile tubes and frozen. Aliquots 
were cultured and tested for pyrogens in rabbits. 
FCR Determination. This protocol was approved 
by the University of Michigan Medical Center Com- 
mittee to Review Grants for Clinical Research and 
Investigation Involving Human Beings, and written 
informed consent was obtained from all subjects. 
Preliminarily, a brief history and physical examina- 
tion, CBC (with hematocrit), ESR, test panel, 
urinalysis, and serum SCPN determination (3) were 
obtained. Ten drops of a saturated solution of KI 
was administered orally on days - 1, 0, + 1, and +5. 
Following measurements of the vital signs, height and 
weight, the subjects voided, IV lines were established 
in both arms, and blood for baseline measurements 
was obtained via a stopcock in one line. A carefully 
measured volume of 125I-SCPN was injected rapidly 
into the opposite arm, followed by a rapid wash-in 
with saline for 10 rain. Approximately 12-29 ~Ci was 
injected. With accurate timing EDTA-anticoagulated 
blood was withdrawn through the stopcock at 5, 10, 
15, 30, and 60 min. Additional blood samples were 
obtained at 4, 8, and 24 hr and daily at 8 AM for 7 more 
days. Urine was collected, measured, and aliquoted at 
8, 16, and 24 hr and for 7 days thereafter. On day 7 
triplicate aliquots of all plasma and urine specimens 
were counted on a dual-channel counter together 
with a residual specimen of the injected 125I-SCPN. 
One normal investigator also was injected simulta- 
neously with an approximately equal number of 
counts of Na131I to assess aberrant results caused 
from loss of the radioactive iodine label. 
Data Analysis. Computer programs were em- 
ployed to analyze the data by the methods of 
Nosslin (4), Rice, Campbell et al. (5), and Matthews 
(6). Emphasis was placed on results based on Nos- 
slin's integrated rate equations (method IX), which 
take into consideration, in addition to plasma 
counts, urinary isotype recovery and extravascular 
space volume and turnover. Synthesis rates (SR) 
were calculated as follows (7): 
FCR × plasma volume 
x plasma concentration, 
S R =  
kg 
where the plasma volume was estimated from the 
subject's weight and hematocrit. 
Experimental Subjects. These included five vol- 
unteer healthy adults (three male, two female), the 
67-year-old male SCPN-deficient propositus (G.S.), 
his 62-year-old SCPN-deficient sister (A.P.), and 
his 29-year-old son (L.S.), whose SCPN level was 
more than 2 SD below the mean normal level (about 
halfway between his father's and the mean normal 
value). 
R E S U L T S  
Data obtained from a normal subject injected 
with Na131I immediately after injecting 125I-SCPN 
showed a much more rapid clearance of 131I than of 
125I during the first 4-8 hr. This indicates that the 
results reported were not influenced to a major 
extent by loss of free iodide from the 125I-SCPN or 
degraded 125I-SCPN, although the counts of 1251 in 
the urine at 8 hr suggest that this probably occurred 
to some degree. Based on triplicate plasma a25I 
counts, Fig. 1 shows the mean values observed in 
the five normal subjects and individually in the 
three afflicted family members over the 7-day study 
period. The data have been normalized to indicate 
the percentage of initial plasma counts as deter- 
mined by computer extrapolation to 0 time. It is 
evident that values for the G.S. family members 
generally fall within ---2 SD of the mean normal 
values during the early phase of 1251 clearance, but 
later G.S. and L.S. appear to exhibit slightly more 
rapid clearance and A.P. somewhat slower clear- 
ance than the normal subjects. A more definitive 
assessment of these data is shown in Table I, which 
indicates the FCR results calculated by method IX 
of Nosslin (4). Although falling within the 95% 
confidence limits determined by this small group of 
normal subjects, G.S. has a modestly increased 
FCR, but A.P. shows a decreased FCR. The calcu- 
lations also indicate that SCPN is catabolized 
mainly in the extravascular compartment. 
Table I also indicates that the calculated SCPN 
synthesis rates for G.S. and A.P. both fall well 
outside the 95% confidence range for our normal 
subjects, whereas the value for L.S. is only mod- 
estly below the normal mean. Although G.S. has a 
somewhat higher rate of SCPN synthesis than his 
sister (A.P.), his higher FCR results in a SCPN level 
lower than his sibling's. SCPN is expressed in 
functional units as measured by the method of 
Corbin et al. (3) since the levels in individual 
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Fig. I. Percentage of initial plasma nsI cpm based on measurements of triplicate specimens 
obtained at the designated time periods, the initial value being a computer extrapolation to 
time 0. ( X - - X )  The mean of the five normal subjects; the shaded area delineates ±2 SD 
surrounding these mean values. (O - - -O) Data for G.S.; (at - - -at) data for A.P.; (~- - -A) 
data for L.S. 
subjects were assessed by this technique. Although 
it was ascertained that the injected SCPN was 
biologically active, it is uncertain whether the syn- 
thesis rate can be converted into micrograms in the 
absence of information about whether the purified 
and native SCPNs have exactly the same specific 
activity. 
DISCUSSION 
It has been presumed that a major SCPN defi- 
ciency would be a lethal event in view of its role in 
inactivating such biologically active substances as 
Table I. Fractional Catabolic-Rate and Synthesis-Rate Results 
% FCR Synthesis rate SCPN 
(hr) (U/kg/hr) (U/ml) 
Normal subjects 
No. 1 1.75 28,7t6 377 
No. 2 1.33 16,980 289 
No. 3 0.93 13,850 300 
No. 4 1.28 18,226 342 
No. 5 1.20 26,194 322 
Mean ± SD for 
normal subjects 1.30 ± 0.30 20,973 + 6,350 326 
Patients 
G.S. (propositus) 1.76 4,678 70 
A,P. (propositus' 
sister) 0.87 3,864 75 
L.S. (propositus' son) 1.34 15,334 160 
the anaphylatoxins and kinins. Subnormal levels of 
SCPN activity have been observed in cord sera (8), 
in patients with severe liver disease (9), secondary 
to dextran shock or dengue fever (3), and during 
hemodialysis (10). The G.S. kindred is the only 
reported family with a major, inherited SCPN defi- 
ciency (1). Although the propositus has been af- 
flicted with about 40 attacks of ~mgioedema/urticar- 
ia annually for about the past 20 years, it its of note 
that he and his sister have survived well into their 
seventh decade in reasonably good general health. 
Perhaps this is because they retain at least 20% of 
the normal plasma levels of SCPN activity. It is 
presumed that plasma SCPN is synthesized in the 
liver, but there also is a possibility that the cell 
membrane-associated SCPN-type activity, which 
has been reported to be present in placenta, kidney, 
pulmonary vascular endothelium, and other tissues, 
might be a separate source that exerts a significant 
protective effect (11, 12). 
The survival of this family with demonstrated 
SCPN deficiency also prompts reconsideration of 
the anaphylatoxin inactivation process. Recently it 
has become apparent that porcine C5ade~ arg, the 
product of SCPN cleavage of C5a, not only retains 
substantial chemotaetic activity but also has nearly 
as much vascular permeability enhancing and 
spasmogenic activity in vitro and in vivo as intact 
C5a (13-15). Thus one might question the essential 
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role of SCPN in protecting against the anaphylatoxins 
in this species. However, the intravenous injection of 
cobra venom factor into guinea pigs pretreated with a 
potent SCPN inhibitor results in a rapidly fatal reac- 
tion, which features constriction of bronchial and 
pulmonary vascular smooth muscle. The introduction 
of cobra venom factor alone fails to produce this 
dramatic effect, although extensive complement acti- 
vation occurs (16). Rat C5ades am has greater spasmo- 
genic activity than guinea pig C5a~e~ arg and is rapidly 
lethal after intravenous injection into guinea pigs (16). 
Human C5ade~ am retains about 10% of the chemotac- 
tic activity of C5a, but only about 0.1% of its other 
anaphylatoxic activities are retained (15). Thus SCPN 
deficiency in humans might be expected to enhance 
more prominently the anaphylactic reactions than 
inflammatory responses since vasoactive and smooth 
muscle contracting activity would be markedly in- 
creased in plasma during complement activation. At 
present it is not known how the recently described 
marked affinity of SCPN for hexapeptide enkepha- 
lins (11) might influence manifestations of this en- 
zyme deficiency. 
The present data indicate that the major abnor- 
mality in G.S. kindred is a markedly reduced rate of 
SCPN synthesis. This result is consistent with an 
allelic gene defect, which previous studies of this 
family (I) have suggested is transmitted as an 
autosomal recessive trait. Variations in the FCR no 
doubt influence the SCPN levels but appear to be of 
secondary importance. It has been suggested that 
the FCR of this glycoprotein may be influenced by 
its siliac acid content (17), but we have no data 
concerning the polysaccharide associated with 
SCPN in the G.S. kindred. Because of the limited 
quantity of homogeneous, active SCPN available, it 
was possible to study only five normal subjects. 
Although insufficient to define precisely the normal 
range for FCR and synthesis of SCPN, our data 
appear representative of a larger population in that 
the mean SCPN value of 326 U/ml for our five 
subjects approximates the mean value of 319 U/ml 
which we detrmined previously in a study of 104 
normal individuals. 
One stimulus for conducting this study was the 
possibility that the SCPN-deficient patient G.S. 
might benefit from replacement therapy with par- 
tialty purified SCPN. Attempts to maintain SCPN at 
near-normal levels would be feasible, however, 
only if SCPN has a low FCR, resulting in a substan- 
tial half-life in plasma. Unfortunately this did not 
prove to be the case (Fig. 1). There remains the 
possibility that this type of treatment might acutely 
relieve symptoms resulting from SCPN deficiency. 
This situation in some respects is analogous to hered- 
itary angioedema (HAE), with its attendant deficiency 
in C1 inhibitor (C1 INH) synthesis (18). Ci INH has 
been found to have a relatively high FCR in normal 
persons and even higher levels in HAE patients (18). 
Thus maintenance therapy with C1 INH is not feasi- 
ble, but the intravenous administration of partly puri- 
fied C1 INH can produce a prompt remission of 
symptoms during attacks of HAE (19). There is not a 
very close analogy between SCPN and C1 INH 
deficiency, in that the former is an enzyme and the 
latter an inhibitor. In any case, since G.S.'s attacks of 
angioedema are of fairly short duration and partly 
relieved by epinephrine administration, treatment of 
attacks with SCPN-enriched preparations has not 
been attempted. The patient has not responded to 
stanozolol therapy. 
We conclude that genetic defects in SCPN are 
rare, and total deficiency may be incompatible with 
life, perhaps occurring only in infants who fail to 
survive. Alternatively, total deficiency may be im- 
probable because two sources of the enzyme may 
exist under separate genetic control: one originates 
from the liver and the other from cell membrane- 
associated SCPN-type activity, which has been 
observed in placenta, kidney, pulmonary vascular 
endothelium, and other tissues (11, 12). The latter 
scenario would have a decided advantage for sur- 
vival of the host if SCPN is an essential control 
enzyme in humans. In any case, the partial SCPN 
deficiency we have observed in the G.S. kindred 
presumably led to the development of angio- 
edema/urticaria in the propositus through failure to 
inactivate anaphylatoxins generated through low 
levels of complement activation. 
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